Tesamorelin for Visceral Fat

What does tesamorelin do to visceral fat?

In the pivotal 26-week trial, tesamorelin cut visceral adipose tissue by about 15.2 percent while placebo VAT rose about 5.0 percent (Falutz et al., 2007).

Visceral fat is the deep abdominal fat packed around organs, and it behaves differently from the fat under the skin. The largest completed human dataset comes from Falutz et al., 2007, published in the New England Journal of Medicine (doi:10.1056/NEJMoa072375). In that randomized, placebo-controlled study of adults with excess visceral fat linked to HIV therapy, participants who received tesamorelin saw VAT measured by CT scan drop about 15.2 percent, while the placebo group's VAT increased about 5.0 percent over the same 26 weeks (Falutz et al., 2007).

The effect was specific to the deep abdominal compartment. This is why the compound is studied as a targeted VAT agent rather than a general weight-loss tool.

How does tesamorelin work in the body?

Tesamorelin is a GHRH analog: it signals the pituitary gland to release more of the body's own growth hormone in natural pulses (Falutz et al., 2007).

Instead of injecting growth hormone directly, a GHRH analog acts one step upstream. It tells the pituitary to secrete GH, which then raises circulating IGF-1. The pulsatile pattern is meant to stay closer to normal physiology than direct GH replacement (Falutz et al., 2007). In the tesamorelin trial program, higher GH and IGF-1 signaling tracked with reduced visceral fat, consistent with GH-driven lipolysis in the deep abdominal compartment (Falutz et al., 2007).

Other peptides in the GH-secretagogue and GHRH family share this upstream mechanism. CJC-1295, a related GHRH analog, produced sustained GH and IGF-1 elevations in early human work (Teichman et al., 2006), and ipamorelin was characterized as a selective GH secretagogue in preclinical study (Raun et al., 1998). Among this broad class, tesamorelin is the member with the strongest completed human VAT evidence (Falutz et al., 2007).

Is tesamorelin FDA approved?

Yes, tesamorelin is FDA approved as Egrifta for reducing excess abdominal fat in adults with a specific fat-redistribution condition associated with HIV therapy (US FDA, 2010).

The approval was granted in 2010 and rests on the tesamorelin trial program, including the Falutz et al., 2007 study and its extension work (US FDA, 2010; Falutz et al., 2007). That approved use is narrow and disease-specific. Outside that population, human data on tesamorelin for visceral fat is limited, and use in other groups has not been established in completed trials. Statements here describe what the published research reports, not a treatment recommendation.

What doses did the research report?

In the pivotal trial, participants received tesamorelin by daily subcutaneous injection at the dose below; this is research-reported context, not a dosing instruction (Falutz et al., 2007).

These figures describe one trial population. They are not a target for any individual. A qualified clinician is the correct source for any personal decision about whether, when, or how a compound like this would be used.

How does tesamorelin compare with GLP-1 fat-loss agents?

Tesamorelin targets the visceral fat compartment through GH signaling, while GLP-1 and dual-agonist drugs drive broad body-weight loss through appetite and metabolic pathways (Falutz et al., 2007; Wilding et al., 2021).

The two classes are not interchangeable. In obesity trials, semaglutide produced about 15 percent mean total body-weight loss (Wilding et al., 2021), and tirzepatide reached up to about 22.5 percent (Jastreboff et al., 2022). Tesamorelin was not studied for total body weight in the same way; its reported outcome is a specific VAT reduction of about 15.2 percent (Falutz et al., 2007). One measures total pounds, the other measures a fat depot on CT imaging, so the numbers answer different questions.

What are the reported safety signals?

The main biological caution for GH-raising compounds is their effect on glucose and insulin sensitivity, which appears across the class (Nass et al., 2008).

Raising GH and IGF-1 can shift glucose handling. The oral secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity in older adults (Nass et al., 2008), a signal worth noting for any agent that increases GH output. Tesamorelin's approved use includes clinician monitoring, and its labeling reflects the HIV-specific population studied (US FDA, 2010). This page is educational and does not assess safety for any individual.